NMN oral bioavailability: what the 2024-2025 plasma response trials show

← Back to articles

Nicotinamide mononucleotide reached store shelves before its human pharmacology was mapped. The marketing premise is simple: NMN is one enzymatic step away from NAD+, the redox coenzyme that declines with age, so swallowing NMN should top NAD+ back up and, by extension, slow some part of aging. The first half of that chain — that oral NMN raises blood NAD+ — now has reasonably consistent human support. The second half — that the NAD+ rise produces a benefit you can feel or measure — does not. That gap is the whole story, and the recent trial record makes it clearer rather than narrower.

Does oral NMN actually reach the blood?

The long-standing pharmacology objection is that NMN, a charged phosphorylated molecule, does not cross the intestinal wall intact and is instead broken down to nicotinamide riboside and nicotinamide before absorption, then rebuilt into the NAD+ pool inside cells. Human data are consistent with this. In a 12-week placebo-controlled trial of 250 mg/day in healthy adults, Okabe and colleagues found that whole-blood NAD+ rose significantly — but NMN itself did not increase in blood. What rose alongside NAD+ was nicotinic acid mononucleotide, a downstream salvage-pathway intermediate, implying that the swallowed NMN is metabolized before or during absorption rather than circulating as intact NMN [1]. In practical terms, you are not "delivering NMN to your cells"; you are feeding the NAD+ salvage pathway with raw material that happens to start as NMN.

Dose, duration, and how big the NAD+ rise really is

The cleanest dose-response data come from a 60-day randomized, multicenter, double-blind trial in 80 healthy middle-aged adults that tested placebo against 300, 600, and 900 mg/day. All three doses raised blood NAD+ significantly versus placebo by day 30 and day 60, with the response largest at 600 and 900 mg and little additional gain from 900 over 600 — i.e., a plateau around 600 mg/day [2]. Smaller single-arm and placebo-controlled studies at 250 mg/day reach the same qualitative endpoint, a clear NAD+ rise that is well tolerated over 8–12 weeks [1][3]. So the bioavailability question, narrowly defined, has a reassuring answer: enough usable precursor survives the gut to move the NAD+ needle. The size of that move is real but modest, and it is the NAD+ pool that climbs, not circulating NMN.

What the NAD+ rise has, and has not, produced

This is where the marketing outruns the data. A 2024 systematic review with meta-analysis of 12 randomized trials (513 participants) found that NMN reliably elevated blood NAD+ but produced no significant improvement in fasting glucose, triglycerides, total cholesterol, LDL, or HDL — and graded most of the underlying trials as having "some concerns" or high risk of bias, concluding that the benefits of NMN have likely been exaggerated [4]. Functional endpoints are similarly underwhelming. In a 24-week placebo-controlled trial in older men with diabetes and already-reduced grip strength or walking speed, 250 mg/day was safe but did not improve grip strength or gait speed; a hint toward reduced frailty did not reach significance [5]. A 12-week trial reported a tendency toward reduced arterial stiffness that was not statistically significant between groups [6]. The dose-finding trial above did report a longer six-minute walk distance in the NMN arms, but it used a per-protocol analysis and an industry-funded design, so it is best read as hypothesis-generating rather than confirmatory [2].

Metabolic signals: small, inconsistent, mostly in subgroups

A few studies hint at metabolic effects in specific subgroups. An 8-week open-label study in healthy middle-aged Japanese men found that NMN modestly blunted postprandial insulin spikes, but only in the three participants who over-secreted insulin after a glucose load — a finding too small to act on [6]. The broader pattern across the controlled literature is the one the meta-analysis captured: NAD+ goes up, clinically meaningful outcomes mostly do not. Whether NAD+ repletion matters more in genuinely deficient or much older populations, over years rather than weeks, remains untested.

Safety and regulatory status

Short-term safety is the most solid part of the file. Across the trials above, NMN at 250–900 mg/day for 8–24 weeks produced no serious adverse events and no consistent abnormalities on laboratory testing [1][2][5]. Long-term safety (years) is simply unstudied. Separately, the U.S. FDA concluded in late 2022 that NMN cannot lawfully be marketed as a dietary supplement because it had been authorized for investigation as a drug before supplement marketing began; the products remain widely sold amid unresolved regulatory and industry dispute, but the legal status is genuinely uncertain and a buyer cannot assume FDA oversight of a given product's identity or purity.

Bottom line for a buyer

If the question is "does oral NMN raise NAD+," the honest answer is yes, modestly, with a plateau near 600 mg/day. If the question is "will that make me healthier, stronger, or younger," the controlled human evidence does not support it yet. NMN is well tolerated short-term but expensive, of contested legal standing, and unproven for any functional or anti-aging endpoint. There is no trial basis for treating it as anything more than an experimental NAD+ booster.

Sources

1. Okabe K, Yaku K, Uchida Y, et al. "Oral Administration of Nicotinamide Mononucleotide Is Safe and Efficiently Increases Blood Nicotinamide Adenine Dinucleotide Levels in Healthy Subjects." Frontiers in Nutrition, 2022;9:868640. PMID 35479740. DOI: 10.3389/fnut.2022.868640.
2. Yi L, Maier AB, Tao R, et al. "The efficacy and safety of β-nicotinamide mononucleotide (NMN) supplementation in healthy middle-aged adults: a randomized, multicenter, double-blind, placebo-controlled, parallel-group, dose-dependent clinical trial." GeroScience, 2023;45(1):29-43. PMID 36482258. DOI: 10.1007/s11357-022-00705-1.
3. Katayoshi T, Uehata S, Nakashima N, et al. "Nicotinamide adenine dinucleotide metabolism and arterial stiffness after long-term nicotinamide mononucleotide supplementation: a randomized, double-blind, placebo-controlled trial." Scientific Reports, 2023;13(1):2786. PMID 36797393. DOI: 10.1038/s41598-023-29787-3.
4. Zhang J, Poon ETC, Wong SHS. "Efficacy of oral nicotinamide mononucleotide supplementation on glucose and lipid metabolism for adults: a systematic review with meta-analysis on randomized controlled trials." Critical Reviews in Food Science and Nutrition, 2025;65(22):4382-4400. PMID 39116016. DOI: 10.1080/10408398.2024.2387324.
5. Akasaka H, Nakagami H, Sugimoto K, et al. "Effects of nicotinamide mononucleotide on older patients with diabetes and impaired physical performance: A prospective, placebo-controlled, double-blind study." Geriatrics & Gerontology International, 2023;23(1):38-43. PMID 36443648. DOI: 10.1111/ggi.14513.
6. Yamaguchi S, Irie J, Mitsuishi M, et al. "Safety and efficacy of long-term nicotinamide mononucleotide supplementation on metabolism, sleep, and nicotinamide adenine dinucleotide biosynthesis in healthy, middle-aged Japanese men." Endocrine Journal, 2024;71(2):153-169. PMID 38191197. DOI: 10.1507/endocrj.EJ23-0431.